Enrolling by invitationPhase 2NCT06723015
Tau PET Outcomes With Anti-amyloid Immunotherapies
Studying Amyloidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Petrice Cogswell, M.D., Ph.D.Mayo Clinic
- Intervention
- 18F-AV-1451(drug)
- Enrollment
- 135 enrolled
- Eligibility
- 50-90 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- Mayo Clinic, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06723015 on ClinicalTrials.govOther trials for Amyloidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07560306[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid CardiomyopathyBrigham and Women's Hospital
- RECRUITINGNCT07494656A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in GermanyPfizer
- RECRUITINGPHASE2NCT07285044The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasMayo Clinic
- RECRUITINGNCT07218705A Study Of MCG In Cardiac AmyloidosisMayo Clinic
- RECRUITINGNCT07213297Comprehensive Program for Hereditary Transthyretin AmyloidosisHospital de Alta Complejidad en Red
- RECRUITINGPHASE1NCT06790394Test-retest Study With [18F]FBB in Cardiac AmyloidosisLife Molecular Imaging GmbH
- RECRUITINGNANCT07112066Multimodality Cardiac Imaging for Disease Progression in ATTR-CMDominik Benz
- RECRUITINGPHASE3NCT07207811CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNovo Nordisk A/S